Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
CHMP backs Minoryx's rare disease drug two years after rejection - European Biotechnology Magazine
1+ day, 19+ hour ago (421+ words) Spanish biotech Minoryx Therapeutics has secured a positive European regulatory opinion for Nezglyal, two years after regulators rejected an earlier application for the rare neurodegenerative disease drug. Why it matters: The comeback gives Minoryx a potential route to the first…...
Sanofi drops eczema drug from $1.1B Kymab deal - European Biotechnology Magazine
1+ day, 20+ hour ago (313+ words) Sanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments. Why it matters: Amlitelimab was the principal asset behind Sanofi’s $1.1 billion…...
Iceland-based Synaptiq launches with Nobias' rare disease drug - European Biotechnology Magazine
1+ day, 20+ hour ago (424+ words) Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades. The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans…...
Fresenius launches €200M healthcare venture fund - European Biotechnology Magazine
2+ day, 18+ hour ago (466+ words) German healthcare group Fresenius has created a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years. Why it matters: The fund adds more than €200 million of potential strategic capital to…...
Neurimmune turns future royalties into $425m pipeline cash - European Biotechnology Magazine
3+ day, 22+ min ago (559+ words) Swiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest in its remaining antibody pipeline. Why it matters: The deal…...
Novartis drops Phase 2 radioligand therapy - European Biotechnology Magazine
4+ day, 27+ min ago (273+ words) Why it matters: The Swiss pharma told Fierce Biotech that it had stopped all studies of Lu-NeoB, although patients already participating would continue according to their trial protocols. Zoom in: Lu-NeoB used lutetium-177 to deliver radiation to tumours expressing GRPR,…...
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin - European Biotechnology Magazine
4+ day, 20+ hour ago (753+ words) U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings. The traditional view of cancer…...
Immitra Bio raises CHF 2.4M for in-vivo gene editing - European Biotechnology Magazine
4+ day, 20+ hour ago (402+ words) Swiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders. Why it matters: The ETH Zurich spinout is trying to replace the complex process used by…...
Brenus adds €11M to colorectal cancer vaccine development - European Biotechnology Magazine
5+ day, 22+ min ago (363+ words) French biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its platform. Why it matters: The Lyon-based biotech is trying to bring…...
RNA medicine enters its second act - European Biotechnology Magazine
5+ day, 17+ hour ago (992+ words) “RNA therapeutics were actually being developed in oncology well before COVID-19,” explains Jon Moore, Chief Scientific Officer of Epitopea. “Companies such as BioNTech and Moderna had already been working on personalised cancer vaccines for many years before the pandemic, with…...